We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.

Current Opportunities

San Francisco, CA
Closes: 22 Sep 2024 16:01
San Francisco, CA
Closes: 14 Sep 2024 16:05
San Francisco, CA
Closes: 14 Sep 2024 16:04
San Francisco, CA
Closes: 31 Aug 2024 11:31
San Francisco, CA
Closes: 25 Aug 2024 12:23
San Francisco, CA
Closes: 24 Jul 2024 11:37
San Francisco, CA
Closes: 24 Jul 2024 11:33
San Francisco, CA
Closes: 24 Jul 2024 11:29
San Francisco, CA
Closes: 10 Jul 2024 12:49
San Francisco, CA
Closes: 06 Jul 2024 10:19
San Francisco, CA
Closes: 06 Jul 2024 10:12
San Francisco, CA
Closes: 06 Jul 2024 10:12
This site is powered by SnapHire (www.snaphire.com)